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Abstract 
 
 
Atrial fibrillation (AF) is a clinically heterogeneous arrhythmia that is currently 
classified according to the variety of temporal rhythm based manifestations 
observed clinically, including ‘first detected episode’, ‘paroxysmal’, ‘persistent’ or 
‘permanent’ AF. Despite being widely adopted by the most recent consensus 
guidelines, the utility of this classification system to stratify patients into distinct 
and clinically useful groups that have different outcomes including mortality, 
morbidity, specific cardiovascular outcomes and quality of life, remains 
questionable. This is particularly true regarding the distinction between 
paroxysmal and persistent AF. Here, we demonstrate there is limited and 
conflicting evidence that this distinction is useful in predicting mortality, 
morbidity (including stroke and heart failure), symptom burden and quality of life, 
although there is convincing evidence that patients with paroxysmal AF have 
favourable outcomes following electrical cardioversion and have better ablation 
procedural outcomes. Risk stratification schemes including the CHA2DS2VASc 
score are widely used to help clinicians stratify patients at high risk of stroke, 
whilst a number of newer, potentially superior, competitors have also recently 
been developed. A range of parameters including left atrial (LA) size, LA 
morphology, LA fibrosis (assessed by MRI) LA appendage morphology and LA 
function (assessed by echo) have all been recently suggested to identify higher 
risk patients and may, perhaps in combination with validated risk stratification 
scores and emerging genetic data, provide clinicians with the information 
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necessary to more accurately stratify patients to ensure better outcomes of 
specific AF treatments and prevent adverse events.  
 
 
 
 
Key-words: arrhythmia; mortality; stroke; catheter ablation; cardioversion.  
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Introduction  
 
 
Atrial fibrillation (AF) is a common cardiac arrhythmia and a major public health 
problem currently estimated to affect 1-2% of the population in the developed 
world. Its incidence and prevalence is set to increase significantly as the 
population ages1.  AF is strongly associated with ischaemic stroke2, increased all-
cause mortality3 and carries a substantial socio-economic burden45. Despite major 
advances in our understanding of the pathogenesis and natural history of AF, the 
classification system currently used to categorize AF has remained relatively 
unchanged over recent decades. When used effectively, classifying disease into 
clinically discrete subtypes can be helpful in guiding management decisions as 
well as in selecting patients for inclusion in randomized control trials. However, 
the validity, reliability and clinical utility of the current temporal pattern based 
classification system of AF (Table 1), particularly into paroxysmal vs. persistent 
AF, remains questionable6. This paper aims to examine the clinical utility of the 
current classification of AF into paroxysmal vs. persistent, and explore the 
alternative classification methods currently under investigation.  
 
 
Current AF classification  
 
 
Since the 2001 joint American Heart Association (AHA), American College of 
Cardiology (ACC) and European Society of Cardiology (ESC) consensus guidelines 
AF has been classified as a first detected episode, paroxysmal, persistent or 
permanent7. This forms the basis of the current classification system based on 
temporal rhythm patterns seen in AF and has become the most widely adopted 
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classification system worldwide, still present in the most recent ACC/AHA8 and 
ESC/EHRA9 guidelines. AF has previously been classified in a variety of ways, 
including the underlying pathology (such as myocardial infiltration or 
inflammation, atrial scar, atrial stretch, hormonal, thyroid disease, or idiopathic or 
‘lone AF’), ventricular rate (e.g. fast AF and slow AF), and ECG features (e.g. high 
amplitude “coarse AF” and low amplitude “fine AF”)6.  In addition, post-operative 
AF, a common complication following cardiac surgery10, is often considered as a 
distinct clinical entity with differing treatment and prognosis, and is outside the 
scope of this report.  
 
In patients with untreated or ineffectively treated AF, a proportion of patients will 
revert to sinus rhythm spontaneously whilst some patients will remain in AF 
permanently11. This clinical heterogeneity has been recognized for almost a 
century, with the terms “paroxysmal” and “chronic” used to described AF as early 
as the 1920s 12, and used widely throughout the 20th century. Lewis was the first 
to formally recognize this phenomenon in 1922, stating that AF (then termed 
‘auricular fibrillation’)  “...was known to exist in two forms: in the form of short 
paroxysms, lasting a few hours or a few days, and much more often as a malady 
persisting until death. The view was held that if auricular fibrillation had lasted ten 
days, then it was a settled thing” and suggested that “...once established for a few 
weeks, the prospect of it’s spontaneous passage is beyond reasonable explanation.”12. 
This prompted the introduction of the term ‘chronic AF’, which was widely used 
throughout the 20th century.  
 
  6 
However, given that patients can alternate between AF and sinus rhythm over 
many years, the use of “chronic” AF became unpopular as, despite AF being a 
chronic disease in such patients, they are not permanently (“chronically”) in AF. 
Furthermore, with the wide application of electrical and pharmacological 
cardioversion, patients with previously “chronic” AF could be effectively returned 
to sinus rhythm, as cardioversion could be repeated whenever deemed 
appropriate13. Additionally, a significant proportion of patients with “paroxysmal 
AF” may progress to persistent AF (15% in the first 12 months of follow up in one 
large prospective study of over 1200 paroxysmal AF patients14).  
 
There is also marked clinical variability within paroxysmal AF, with some patients 
having very few  short-lived episodes, whilst others have longer periods of AF and 
short periods of sinus rhythm. However, the cumulative time spent in AF, termed 
the ‘AF density’15, has been difficult to accurately measure, given that most 
outpatient investigations provide only a ‘snapshot’ view of the heart’s rhythm15, 
and even 24-hour Holter Monitor tests still underestimate AF density and 
overestimate success following ablation procedures15. Information from 
implantable cardiac devices (pacemakers and defibrillators), or implantable loop 
recorders can enable more precise quantification of AF burden if the sensing 
algorithms are optimised, and may provide insight into the development of AF 
over time16,17, but these methods are not applicable to the global population of AF 
patients. 
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Early data on AF episode duration and thromboembolic risk were contradictory, 
but it is now almost accepted that patient-related risk factors included in current 
risk stratification schemes (e.g. CHA2DS2VASc) are more important than AF type 
(paroxysmal or persistent). To date few studies have shown an association with 
the current AF classification and thromboembolic risk (Table 3).  
 
Much of the scrutiny into the limitations of categorizing AF as either paroxysmal 
or chronic came in the 1990s. In 1995 Samuel Levy suggested a new classification 
system for paroxysmal AF that took into consideration an estimate of the 
frequency and duration of AF episodes, in order to better reflect risk.18. However, 
Levy’s classification system only aimed to separate patients into different 
subtypes of paroxysmal AF based on risk, and therefore did not reflect the broad 
heterogeneity of all temporal patterns seen in AF. In 1998 Gallagher and Camm 
suggested an updated temporal rhythm based classification aiming to cover the 
majority of eventualities13, introducing the terms “persistent” and “permanent” 
alongside paroxysmal and first onset (acute) AF.  
 
Paroxysmal AF was described as cases in which episodes of AF terminate 
spontaneously, and the authors decided not to subdivide this category further, as 
previously suggested18, arguing instead that the typical frequency and duration 
should be described for each individual patient, given the continuous nature of 
each variable. “Persistent AF” was used to describe AF which continues until a 
measure is taken to terminate it, whilst AF was described as “permanent” when 
all attempts to restore sinus rhythm had failed or when the patient and physician 
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decide that no such attempt should be made13. These four categories form the 
basis of the classification system currently used by the ACC, AHA and ESC (EHRA), 
which was first endorsed in 20017. The definitions currently used to classify AF by 
the ACC/AHA/ESC/EHRA and their evolution over time are shown in Tables 1 and 
2 respectively. 
 
 
Evidence base for current definitions of paroxysmal vs. 
persistent AF 
 
 
Despite a wide adoption of this temporal rhythm based classification of AF, most 
probably because of its simplicity and clinical convenience, there has been a 
limited number of studies directly investigating whether this is clinically helpful 
in predicting differences in AF-related morbidity or mortality. This is particularly 
true when distinguishing between paroxysmal and persistent AF.  
 
Morbidity, stroke and heart failure  
Stroke is 3 to 5 times more common in patients with ‘non-valvular’ AF compared 
to those without electrophysiological abnormalities6,19,20, and a number of studies 
have looked at whether temporal rhythm based AF class can be used to further 
stratify patients at increased risk of stroke. Patients with ‘valvular’ AF, which has 
been defined as AF in the presence of either a bioprosthetic heart valve or mitral 
stenosis, is associated with a significantly increased risk of thrombo-embolic 
events, and is discussed in detail elsewhere21.  
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During the early 1980s it was generally considered that only paroxysmal AF was 
strongly associated with thromboembolism22. However, it was then shown that a 
comparable risk of embolism was also present in ‘chronic AF’23, and that temporal 
rhythm based classification of AF does not predict risk of stroke24,25,26,27,28, but 
much of the data comes from before the standardization of the definitions 
currently used 29,30,31,32,33. Furthermore, a number of study limitations have been 
suggested to account for these findings, including imbalances in antithrombotic 
prescribing rates between groups in the GISSI-AF24 and ACTIVE-W27 studies34. 
Later epidemiological studies then contradicted earlier findings, suggesting 
instead that more chronic forms of AF were in fact associated with a higher risk of 
thromboembolism than paroxysmal AF 35,36.  
 
With the development of various thromboembolism risk-stratification schemes 
such as the CHADS237 and the refined CHA2DS2-VASc38, it was then found that 
commonly established risk factors for thromboembolism such as previous 
stroke/TIA, patient age, hypertension and diabetes, were better predictors of 
outcome than temporal rhythm based classes of AF6,39.  These scores allow a 
moderate estimation of the risk of stroke, and a number of recently developed risk 
scores aim to provide a more accurate tool for risk stratification. These include the 
ATRIA40, Framingham41 R2CHADS (derived from the ROCKET-AF cohort42), ABC-
stroke (derived from ARISTOTLE43) and the ENGAGE-AF biomarker risk score44, 
all of which have been suggested to be more effective than previous scores in their 
preliminary validation cohorts. However, to date these risk scores only assess the 
risk of stroke and none are able to clarify different bio-phenotypes of patients with 
substrates of AF, and therefore, they are likely to be unable to replace the 
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paroxysmal/persistent AF classification for that purpose. Despite this, these 
scores are able to successfully discriminate between high and low risk patients, 
yet none rely on the temporal rhythm based AF class. 
 
More recently, however, a study by Steinberg et. al, again demonstrated a 
significantly increased risk of stroke in patients with persistent compared with 
paroxysmal AF34. This finding was supported by the ARISTOTLE trial comparing 
the outcomes of apixaban vs. warfarin between AF subtypes, which showed a 
significantly lower risk of stroke or systemic embolism for paroxysmal AF than for 
persistent or permanent AF  (HR: 0.70, 95% CI (0.51, 0.93), P = 0.015)45. In 
addition to stroke, silent cerebral infarcts have also been recently shown to be 
more than twice as common in patients with AF than those without, but this 
association was independent of AF type (paroxysmal vs. persistent)46.   
 
Similarly, congestive heart failure is considerably more common in patients with 
AF, in part because they share similar risk factors, but also because one may 
directly predispose to the other47. Furthermore, the concomitant presence of both 
symptomatic heart failure (with reduced or preserved systolic function) and AF is 
associated with significantly worse cardiovascular morbidity and mortality48. 
 
 The strongest data to date, from the Euro Heart Survey, which prospectively 
followed a cohort of over 4000 patients with AF over 1 year, demonstrated similar 
rates of new-onset heart failure in patients with paroxysmal and persistent AF26. 
By contrast, the ARISTOTLE trial (which included almost 16,000 patients and 
therefore had more statistical power to show small differences) showed that 
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patients with persistent AF were more likely to have a history of heart failure than 
patients with paroxysmal AF45.  
 
Given the conflicting reports discussed, it is currently unclear whether the 
temporal rhythm based categories of paroxysmal and persistent AF are useful in 
predicting risk of stroke or heart failure.  
 
Mortality  
A number of studies have examined the relationship between class of AF and 
mortality. Overall, the data shows that patients with permanent AF have a worse 
prognosis than those with other patterns26,49,50,51, but there is an unclear 
difference between patients with paroxysmal vs. persistent AF26. Some studies 
have suggested a reduced mortality in persistent compared with paroxysmal 
AF49,52, whilst others have demonstrated a reduced all-cause mortality in 
paroxysmal AF compared with persistent AF 34. These differences may be due to 
misclassifications of AF pattern, as again the majority of these studies did not 
strictly follow the definitions currently used to define paroxysmal and persistent 
AF, cohorts with different risk profiles, or unaccounted confounding variables. 
Therefore, the ability of the paroxysmal and persistent AF classification to 
differentiate between two groups of patients with different prognosis also 
remains unclear. 
 
Symptoms and quality of life  
Improving quality of life (QoL) is becoming increasingly recognised as an 
important component of a comprehensive treatment plan as well as an outcome 
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measure in studies investigating the efficacy of therapeutic interventions in AF53. 
QoL is impaired in the majority of patients with AF, largely due to the distress 
caused by symptom onset (including palpitations, chest pain, dizziness and heart-
failure-like symptoms) 53,54, and can be improved by both rate and rhythm control 
strategies55.  
 
Investigation into QoL in AF in Spain showed that QoL varied significantly by 
clinical characteristics of the disease but there was no difference between 
paroxysmal, persistent and permanent AF, except patients with permanent AF 
scored highest (better QoL) on psychological dimensions56. Better psychological 
QoL scores in more long-standing AF is perhaps because such patients, 
particularly with permanent AF, typically have more stable heart rate profiles 
with fewer paroxysmal changes and hence fewer symptomatic episodes over time, 
reducing the associated stress and anxiety53,57.  
 
The Canadian Cardiovascular Society (CCS) developed a Severity of Atrial 
Fibrillation (CCS-SAF) in order to characterize patients’ symptom severity and 
effect on wellbeing58. Patients were categorized by AF type  (paroxysmal vs. 
persistent/permanent) and QoL was found to vary significantly by AF pattern, 
with patients with persistent or permanent AF reporting worse QoL than patients 
with paroxysmal AF58. By contrast a French study, again before the 
standardization of classification systems, showed that patients with paroxysmal 
AF (defined as “recurrent episodes of AF lasting >2 minutes and <7 days” and 
including patients with a first episode of AF lasting <7days or cardioverted within 
7 days) were significantly more symptomatic than patients with ‘chronic AF’ 
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(defined as AF present for >1 month)29. These conflicting results may in part be 
confounded by the concomitant use of rate or rhythm control drugs that reduce 
adverse effects.  
 
Predicting outcomes following ablation 
Classifying AF as either paroxysmal or persistent successfully differentiates 
between two groups of patients with different outcomes in AF ablation. This is 
supported by convincing data from observational studies59 and large randomized 
controlled trials showing that catheter ablation is less successful for persistent AF 
than for paroxysmal AF59,60. Data from the Leipzig Heart Centre AF Ablation 
registry, which studied over 2000 patients also showed persistent AF to be an 
important predictor of AF recurrence at 12 months61. Indeed, data from Chao and 
colleagues show that long-term success rates after a single ablation procedure in 
non-paroxysmal AF may be as low as 25%, and multiple procedures are often 
required62. 
 
As such, a number of scoring systems aiming to predict the success of ablation, 
such as the APPLE63, BASE-AF264, and MB-LATER65 scores, include the temporal 
rhythm based classification of AF, with persistent AF a predictor of poorer 
outcomes. Age, renal dysfunction, LA enlargement, BMI, duration of AF, current 
smoking status, left bundle branch block and male gender are among the other 
variables incorporated into these scores.” 
 
These findings are reflected by the current (2012) HRS/EHRA/ECAS expert 
consensus guidelines on catheter and surgical ablation of atrial fibrillation, which 
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suggest that catheter ablation is “recommended” in paroxysmal AF (Class of 
Recommendation: I; level of evidence: A) and “reasonable” in persistent AF (Class 
of Recommendation: IIa; level of evidence: B)66. In contrast with the most recent 
ESC and AHA/ACC guidelines, this consensus provides slightly different 
definitions for paroxysmal and persistent AF (Table 2). Briefly, the authors 
suggest including patients with continuous AF who undergo cardioversion within 
48 hours of AF onset as having paroxysmal AF, and persistent AF if the 
cardioversion is performed more than 48 hours but less than one week after the 
onset of AF66.  
 
Is there a mechanistic basis for a symptom-based classification? 
It was suggested that the lower success rate of persistent AF compared with 
paroxysmal AF ablation may be explained by a mechanistic difference between the 
two forms, with paroxysmal AF considered to show a predominance of local 
triggers/drivers, particularly from the pulmonary veins (PVs), whilst in persistent 
AF re-entrant substrates (initially functional and then structural) predominate 
following electrical & structural remodeling of the atria67. This was supported by 
early reports of significantly improved efficacy of pulmonary vein isolation in 
paroxysmal AF compared with persistent AF68.  
 
In addition, structural remodeling of the left atrium has been shown to correlate 
with reduced electrogram amplitude in these areas69. In keeping with previous 
findings, more of these low voltage sites were seen in persistent AF, which may 
help individualize ablation strategies in such patients69. According to data from 
Marrouche and colleagues, the amount of atrial tissue fibrosis, estimated by 
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delayed enhancement MRI, is independently associated with likelihood of 
recurrent arrhythmia70. 
 
Recent investigations into catheter ablation in patients with persistent AF in the 
STAR-AF II trial59 showed that pulmonary vein isolation alone can achieve a 
successful outcome in approximately half of all patients with persistent AF, and 
that no additional benefit was obtained from additional linear or complex atrial 
fractionated potential ablation. However, these data are contested as many 
patients were in an early phase of persistent AF.  
 
The failure of these trials to demonstrate the benefit of ablation beyond 
pulmonary vein isolation most probably reflects the heterogeneity of mechanisms 
involved, degree of atrial structural remodeling and limitations in current 
mapping technologies to define them, as well as the limitations of ablation as an 
appropriate strategy in all cases.  
 
Whereas for paroxysmal AF pulmonary vein isolation can achieve a high rate of 
“cure” from AF relapse, things are more difficult to interpret in persistent AF. 
Approximately 50% of patients at 12 months do well with pulmonary vein 
isolation, suggesting that they present with pulmonary vein-dependent persistent 
AF. On the other hand, other patients presenting with relapse can represent one 
of two groups: (1) patients with involvement of other triggers or circuits outside 
the pulmonary veins, and which could not be effectively neutralized with the 
ablation technology (non-contact-force sensing radiofrequency), and strategies 
used (ablation of complex fractionated potentials acquired through the automatic 
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NAV-X mapping algorithm, and linear ablation), or (2) patients with pulmonary 
vein-dependent persistent AF, whose veins reconnected following ablation.   
 
Whilst there is considerable evidence to suggest a gradual evolution in the 
mechanisms driving AF over time, it still is unclear how the current classifications 
of AF into paroxysmal and persistent relate to this.  
 
Is the 7 day limit useful? 
AF is described as paroxysmal when lasting < 7 days, and persistent or permanent 
when lasting > 7 days (Table 1). This 7-day cutoff has been suggested to be useful 
in predicting the likelihood of spontaneous cardioversion or successful chemical 
or electrical cardioversion. Newer onset AF (<7 days) is considered to have an 
increased chance of successful cardioversion than more longstanding (persistent) 
AF71. However, a range of studies have examined different cutoffs for recent-onset 
AF, including <24h72,73, <72h73 and <2 weeks72. All of these studies demonstrate 
that a shorter duration of AF is associated with increased chance of cardioversion. 
One study looking at the likelihood of spontaneous cardioversion within 72h 
found presentation with symptoms of <24h duration was the best predictor of 
spontaneous cardioversion73.  
 
In the development program of vernakalant, the 7-day cutoff was used to separate 
AF of short duration (3 hours to 7 days), and long duration (8 days to 45 days)74,75. 
No justification was given for the 7 day cutoff, but, interestingly vernakalant was 
more effective in cardioverting patients in the short AF duration group (over 50% 
success), than in the long AF duration group (less than 10%)74,75. 
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Furthermore, chemical and electrical cardioversion have shown higher success 
rates when AF has existed for a shorter time. Chemical cardioversion by flecainide 
was shown to be significantly more successful in patients with an onset of AF <24 
h compared with AF of longer duration76. Furthermore, amiodarone was shown to 
cardiovert 85% of patients with AF lasting < 1 year, compared to 57% in patients 
with AF lasting longer than 1 year77, and similar findings have shown that 
electrical cardioversion is also more successful in AF of shorter duration78. 
 
Investigation of a goat model demonstrated that the length of artificially induced 
AF correlated with the duration of sustained AF following termination of the 
artificial AF79. Long-term sustained AF was a far more likely outcome following 2 
weeks of sustained induced AF than following shorter episodes of induced AF, 
where spontaneous conversion to sinus rhythm was common79. Furthermore, the 
authors demonstrated a direct electrophysiological correlation between the atrial 
effective refractory period and the duration of the arrhythmia, demonstrating that 
AF promotes optimal electrophysiological conditions that favour further 
propagation of the arrhythmia. This prompted the widely accepted suggestion 
that “atrial fibrillation begets atrial fibrillation”79, and provides a 
electrophysiological explanation for the association between time spent in AF and 
likelihood of conversion to sinus rhythm.  
 
In summary, whilst there is strong evidence to demonstrate an association 
between time spent in AF and likelihood of cardioversion, the 7-day distinction 
between paroxysmal and persistent AF is arbitrary. The ESC AF guidelines state 
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that the 48 hour time point is clinically important in predicting the likelihood of 
spontaneous conversion to sinus rhythm, which falls significantly after 48 hours, 
and that anticoagulation should be considered after this cutoff80. There is strong 
evidence seems to support this73, which raises the question of why the 48-hour 
mark is not used as a clinically significant differentiator between AF classes. This 
cutoff seems already to be slowly making its way into some of the expert 
consensus documents mentioned above66. Furthermore, the 24h time point may 
be the most useful in predicting the probability of successful cardioversion.  
 
 
Future direction: towards improved AF classifications 
 
Clinical disease classification schemes should be able to discriminate between 
patients in order to inform clinical management decisions and predict the 
prognosis.  As discussed, the current temporal rhythm based classification of AF 
is of limited or unclear value in this respect, and requires further investigation. By 
contrast, traditional risk stratification schemes such as CHA2DS2-VASc, 
particularly with the incorporation of cardiac biomarkers including troponins 
(raised in myocardial injury), BNP (raised in myocyte wall stress), amongst 
others81, may help to identify patients at high risk of thromboembolism43,44. In 
addition, a number of alternative methods of differentiating between subtypes of 
AF already exist, or are currently being investigated, including the emerging role 
AF genetic biomarkers82,83,  that may better distinguish between clinically 
relevant subgroups of patients with AF.  
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Does left atrial size by itself, independent of LA function, have any 
relevance? 
Using data from the Framingham Heart Study, a study published in 1995 showed 
that, on multivariate analysis, left atrial enlargement remained a significant 
predictor of stroke in men, and death in both sexes84. Notably, this increased risk 
was not restricted to subjects with AF and eliminating such subjects did not 
significantly alter the association between atrial size and risk of stroke. This 
suggested that atrial size may be more important than atrial function (including 
temporal rhythm based class of AF) in predicting risk of stroke in all patients. 
Furthermore, recent sub-analysis of the ENGAGE-AF trial showed that increased 
left atrial size and higher filling pressures were associated with an increased risk 
of death, but not thromboembolism85.  
 
Recent investigations in this area suggest that the geometry of the left atrium, 
rather than size alone, may be a better predictor of thromboembolic risk86. 
Incorporating this information, termed ‘left atrial sphericity’, into the CHADS2 and 
CHA2DS2-VASc risk scores significantly improves their performance86. 
Furthermore, it has also been suggested that left atrial appendage (one of the main 
sources of cardiac thrombus formation) morphology may also be associated with 
embolic risk, with one study showing that patients with a normal ‘chicken wing’ 
shaped left atrial appendage had a considerably lower risk of thromboembolism87. 
This finding was also supported by a recent meta-analysis including a total of 8 
studies and over 2,500 patients88, suggesting that left atrial appendage 
morphology may indeed offer useful information in predicting risk of 
thromboembolism and guiding anticoagulation management. This is particularly 
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relevant in determining risk for patients with a CHA2DS2-VASc score of 1, where 
the benefits and risks of anticoagulation are more finely balanced versus higher 
CHA2DS2-VASc scores.  
 
Can measures of left atrial function as assessed by echo be of use? 
Certain echocardiogram findings reflecting left atrial function (like low velocities 
in the in the left atrial appendage, spontaneous echocardiographic contrast and 
presence of left atrial thrombus on transoesophageal echocardiogram and left 
atrial strain and strain rate analysis89, which can be performed through 
transthoracic echocardiogram) in AF are associated with an increased risk of 
thromboembolic disease90, and may be helpful in refining and improving the 
accuracy of current risk stratification schemes such as CHA2DS2-VASc91. 
Echocardiography is a widely used and relatively cheap imaging modality making 
this a very promising possibility.  If these techniques provide a reliable surrogate 
of fibrosis, they would be a likely candidate. However a number of unsolved 
questions exist: the transoesophageal echocardiogram is an invasive test and 
therefore cannot be used in the global AF population; assessment of left atrial 
strain and strain rate is difficult and operator-dependent, requiring expertise, and 
no consensus exists regarding the best methodology to assess it92.  
 
Fibrosis assessed by MRI  
Some authors have suggested an important role for fibrotic atrial structural 
remodeling as a potential cause of abnormal atrial activation and hence initiation 
and propagation of AF, with the degree of fibrosis varying widely among 
patients93,94,70. Patients with extensive fibrosis may represent a phenotype of 
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advanced and irreversible atrial myopathy, while patients without fibrosis can 
represent either forms of purely electrical disease (i.e. “atrial chanelopathy”), or 
patients in very early stages of the progression of a fibrotic myopathy. 
 
Fibrosis of the left atrium has been suggested to be a useful predictor for success 
of rhythm control strategies including catheter ablation95,79. Hence, detecting the 
extent of atrial remodeling, which can be effectively achieved by delayed 
enhancement magnetic resonance imaging (MRI), may play an important role in 
differentiating between patients with AF to help predict treatment response and 
guide prognosis. This “UTAH classification” has been associated with outcomes of 
AF ablation96. 
 
Preliminary data suggest that extension of left atrial fibrosis measured through 
MRI may be associated with prior history of stroke in AF individuals97, and with 
the presence of a more pro-thrombotic milieu in the left atrium98. However, the 
association of left atrial fibrosis with major outcomes like stroke, heart failure and 
mortality remains to be proven. 
 
Scoring systems for predicting progression to persistent AF 
A significant proportion of patients with paroxysmal AF will progress to persistent 
AF, and these patients often have worse outcomes than patients with AF who 
demonstrate no progression14. The HATCH score was developed to predict 
progression, based on a number of independent predictors of AF progression 
identified from multivariate analysis of a cohort of 1,219 patients with paroxysmal 
AF (15% of which progressed to more sustained forms over a 12 month-interval), 
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including heart failure, previous transient ischaemic attack or stroke, 
hypertension and chronic obstructive pulmonary disease14. The HATCH score may 
be a useful tool for selecting patients for intensified ECG monitoring99, and may 
also be useful in stroke risk assessment99, but there is currently limited data to 
support this. Recent investigation into the progression of paroxysmal to persistent 
AF in patients awaiting ablation showed that the HATCH score was a poor 
predictor of progression, and multivariate analysis suggested a left atrial diameter 
of >45mm and heart failure were the strongest, independent predictors of AF 
progression100.  
 
Discussion 
 
The current temporal rhythm based classification of AF provides a simple and 
reproducible way of describing the broad range of clinical patterns seen. It has the 
advantage of standardizing the terminology used and has led to the gradual disuse 
of vague terms and misleading terms such as ‘chronic’ AF6. However, as discussed, 
this strategy has a number of important limitations. 
 
Firstly, there is little evidence to show any clinical utility in differentiating 
between paroxysmal and persistent AF in terms of morbidity, mortality, and 
quality of life. Furthermore, despite mechanistic differences between paroxysmal 
and persistent AF the distinction does not support different ablation strategies, 
following the results of the recent STAR-II AF trial59, and the 7 day cut-off which 
forms the basis of these terms appears to be arbitrary. Alternative concepts like 
early persistent AF101  and persistent AF from the onset102, are currently being 
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introduced in routine clinical practice and may contribute to further identify 
different groups of patients with different pathophysiologic bases and likely to 
have a different prognosis, but can also lead to and aggravate some of the 
confusion on classifying patients who present on the borderline between 
paroxysmal and persistent AF ablation, combining features of both forms. 
 
In addition, there is a lack of standardization in multiple aspects of AF 
management, including diagnosis, ECG findings and the methods used to monitor 
the duration and extent of heart rhythm and rate.  This is further compounded by 
continuously evolving AF treatments including new drugs, techniques, procedures 
and devices, with varying patient selection criteria (including the concomitant use 
of drugs to control rate, rhythm and other agents known to affect cardiovascular 
outcomes) and outcomes measured in RCTs to date. As a result, there is a lack of 
RCT data using standardized definitions and approaches for diagnosis, 
monitoring, treatment and outcomes, which limits the evaluation and refinement 
of current AF nomenclature needed to improve patient outcomes.   
 
A number of alternative risk stratification methods are currently being 
investigated. If after thorough investigation, including pilot studies and larger 
RCTs, such methods remain promising and feasible, these approaches may be 
combined with traditional risk stratification systems to provide a more 
individualized, integrated and comprehensive stratgey to determine which 
patients are more likely to respond favourably to particular therapeutic 
modalities. This will only be possible by harvesting high quality data from 
  24 
previous studies as well as appropriately designed, prospective trials following 
the standardized categorization, nomenclature and management of AF.  
 
In addition, recent attempts have been made to more broadly categorize atrial 
pathologies into discrete cohorts based on underlying histopathology as part of 
the spectrum of ‘atrial cardiomyopathies’, defined by a recent expert consensus as 
“Any complex of structural, architectural, contractile or electrophysiological 
changes affecting the atria with the potential to produce clinically-relevant 
manifestations”103. This ‘EHRAS’ classification system may be a more useful way 
of categorizing patients with AF, enable individualized management and improve 
outcomes, but still requires validation103.  
 
 
Conclusion 
 
Apart from being a simple division predicting success of cardioversion and 
pulmonary vein isolation in early onset AF, the current classification of AF into 
paroxysmal / persistent has so far failed to demonstrate a robust association with 
symptom severity, quality of life and cardiovascular outcomes, The cardiology 
community should continue to develop more clinically relevant classification 
schemes that better predict outcomes and support evidence based management 
decisions. 
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Figure legends 
 
Figure 1. Summary of the future directions towards an improved risk 
stratification system for predicting morbidity and mortality in AF  
 
 
